Meropenem

Atomwise Appoints Gavin Hirst, Ph.D., as Chief Scientific Officer

Retrieved on: 
Wednesday, September 14, 2022
Software, Biotechnology, Nanotechnology, Pharmaceutical, Health, Artificial Intelligence, Health Technology, Technology, Lists of diseases, II, PAK, Entrepreneurship, Food, Inflammatory bowel disease, Psoriasis, SYK, Meropenem, Colorectal cancer, Senior, Secondary research, Therapy, Deep learning, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Vaborbactam, CEO, Technology, Interim, Degenerative disease, Turning Point, Artificial intelligence, Takeda, IND, Janssen, Bristol Myers Squibb, Drug discovery, DLBCL, Pharmaceutical industry, Chemistry

Atomwise , a leader in using artificial intelligence (AI) for small molecule drug discovery, today announced the appointment of Gavin Hirst, Ph.D., as Chief Scientific Officer.

Key Points: 
  • Atomwise , a leader in using artificial intelligence (AI) for small molecule drug discovery, today announced the appointment of Gavin Hirst, Ph.D., as Chief Scientific Officer.
  • Gavin brings deep expertise in structure- and fragment-based drug discovery, and a fantastic track record in driving those initial discoveries to become new medicines to help patients.
  • In his new role, Dr. Hirst will set the companys strategic vision for drug discovery and provide scientific oversight of Atomwises research and development pipeline.
  • Atomwise is a technology-enabled pharmaceutical company leveraging the power of AI to revolutionize small molecule drug discovery.

DGAP-News: PAION LAUNCHES ERAVACYCLINE FOR THE TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS IN ADULTS IN GERMANY

Retrieved on: 
Monday, August 1, 2022
IDSA, Philippe Ciais, Anesthesia, Infection, EU, Infectious Diseases Society of America, Ertapenem, Abscess, Distributive shock, ISIN, Remimazolam, Intra-abdominal infection, Angiotensin, Tetracycline, PA8, Royal commission, Eravacycline, Sepsis, Federal Joint Committee (Germany), Septic, Hypotension, Aachen, Product, Abdominal cavity, European Commission, European Medicines Agency, Frankfurt Stock Exchange, Patient, Health, Peritonitis, Multiplicity of infection, Meropenem, ICU, Critical care, Dietary supplement, Pharmaceutical industry, European

In April 2022, the Federal Joint Committee (G-BA) voted in favour of PAIONs application for eravacycline as a reserve antibiotic.

Key Points: 
  • In April 2022, the Federal Joint Committee (G-BA) voted in favour of PAIONs application for eravacycline as a reserve antibiotic.
  • Eravacycline is approved by the European Commission and the UK Medicines Agency for the treatment of complicated intra-abdominal infections (cIAI) in adults.
  • Eravacycline is an important new treatment option for patients suffering from serious intra-abdominal infections.
  • Eravacycline is an antibiotic used to treat complicated intra-abdominal infections (cIAI) in adults.

Melinta Therapeutics and Cidara Therapeutics Announce Licensing Agreement to Commercialize Rezafungin in the U.S.

Retrieved on: 
Wednesday, July 27, 2022
Health, Infectious Diseases, Clinical Trials, General Health, Pharmaceutical, Biotechnology, License, Restore, Physician, DFC, U.S. Securities and Exchange Commission, Food, Forward-looking statement, Fungemia, Partnership, Private Securities Litigation Reform Act, Securities Act of 1933, Securities Exchange Act of 1934, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NDA, Infection, Therapy, Adult, Safety, COVID-19, Agreement, Respect, Mycosis, Minocycline, Prescription Drug User Fee Act, End-user license agreement, Injection, Review, FDA, Security (finance), Patient, Tavarua, LLC, Drug Quality and Security Act, Meropenem, QIDP, PDUFA, Pharmaceutical industry, Hospital, EU, Melinta Therapeutics

Melinta Therapeutics, LLC (Melinta) and Cidara Therapeutics (Cidara) today announced that they have entered into a License Agreement (the Agreement) to facilitate a strategic partnership to commercialize rezafungin, a novel, once-weekly echinocandin antifungal in the United States (U.S.).

Key Points: 
  • Melinta Therapeutics, LLC (Melinta) and Cidara Therapeutics (Cidara) today announced that they have entered into a License Agreement (the Agreement) to facilitate a strategic partnership to commercialize rezafungin, a novel, once-weekly echinocandin antifungal in the United States (U.S.).
  • The NDA will be transferred to Melinta at the time points as specified in the Agreement.
  • The addition of rezafungin expands and diversifies our existing portfolio and serves as fuel for accelerating our long-term growth strategy.
  • Cidara is developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases.

Cidara Therapeutics Submits NDA for Rezafungin and Announces License Agreement with Melinta Therapeutics for Commercialization of Rezafungin in the U.S.

Retrieved on: 
Wednesday, July 27, 2022
Regulation of food and dietary supplements by the U.S. Food and Drug Administration, GLOBE, Restore, Physician, DFC, U.S. Securities and Exchange Commission, Food, CEO, SAN, Fungemia, Forward-looking statement, EMA, Partnership, Private Securities Litigation Reform Act, Securities Act of 1933, Securities Exchange Act of 1934, NDA, Risk, Infection, Therapy, Safety, COVID-19, AstraZeneca, Respect, Mycosis, Minocycline, Prescription Drug User Fee Act, Injection, European Medicines Agency, Review, Caspofungin, FDA, Security (finance), Standard of care, Patient, CDTX, Nasdaq, Collaboration, CMC, Tavarua, LLC, Drug Quality and Security Act, Meropenem, Vaborbactam, QIDP, PDUFA, State, Bank, Pharmaceutical industry, EU, Melinta Therapeutics

The FDA has previously granted Qualified Infectious Disease Product (QIDP) designation to rezafungin for injection which confers priority review of the NDA.

Key Points: 
  • The FDA has previously granted Qualified Infectious Disease Product (QIDP) designation to rezafungin for injection which confers priority review of the NDA.
  • The NDA submission for rezafungin was based on positive results from Cidaras global ReSTORE Phase 3 and STRIVE Phase 2 trials.
  • The NDA submission for rezafungin for the treatment of candidemia and invasive candidiasis is an important milestone for Cidara, said Jeffrey Stein, Ph.D., President and Chief Executive Officer of Cidara.
  • Dr. Stein added, This transaction eliminates the need for Cidara to build commercial infrastructure to launch rezafungin in the U.S.

Global Carbapenem-Based Antibiotics Market Forecast Report to 2028: Rising Prevalence of Gram-Negative Bacterial Infections and Increasing Production of Generic Drugs - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 10, 2022
Infectious Diseases, Pharmaceutical, Health, COVID-19, Population, Distribution, Urinary tract infection, Imipenem, Geography, Market share, Meningitis, Adoption, Vaccine, Infection, Pharmacy, CAGR, Multiplicity of infection, Research, Growth, Pharmaceutical industry, Dietary supplement, Agriculture, Doripenem, Meropenem

The "Carbapenem-Based Antibiotics Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type, Indication, and Distribution Channel" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Carbapenem-Based Antibiotics Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type, Indication, and Distribution Channel" report has been added to ResearchAndMarkets.com's offering.
  • In addition, the expiry of patented carbapenem-based antibiotics has widen-up opportunities for generic drug manufacturers to enter the market with their cost-efficient drugs.
  • The others segment held the largest market share of the carbapenem based antibiotics market in 2021, and it is anticipated to register the highest CAGR in the carbapenem-based antibiotics market during the forecast period.
  • Based on indication, the carbapenem-based antibiotics market is segmented into bacterial meningitis, acute pelvic infections, respiratory tract infections, intra-abdominal infections, urinary tract infections, and others.

Entasis Therapeutics Presents Efficacy and Safety Data from Landmark Phase 3 ATTACK Trial at ECCMID 2022 Conference

Retrieved on: 
Tuesday, April 26, 2022
ACM, Population, Diversified Specialty Institute Holdings, Inc., ABC, Collection, Infection, GLOBE, Patient, Subclinical infection, Entasis, Efficacy, Forward-looking statement, Imipenem/cilastatin, TOC, U.S. Securities and Exchange Commission, Colistin, Meropenem, Private Securities Litigation Reform Act, Complex, Doctor of Philosophy, Mortality, Congress, Acinetobacter, MD, Klebsiella, European, Imipenem, Program, Failure, Nasdaq, Drug of last resort, ITT, Safety, Hospital-acquired pneumonia, Clinical trial, Classification, Nephrotoxicity, Microbiology, MIC, Pharmaceutical industry, Pig, Vaccine, Pseudomonas, Part

In Entasiss first oral presentation, Dr. Alita Miller, PhD, Vice President, Microbiology discussed the Characterization of Acinetobacter baumannii-calcoaceticus complex (ABC) pathogens isolated at baseline from patients enrolled in the ATTACK Phase 3 trial.

Key Points: 
  • In Entasiss first oral presentation, Dr. Alita Miller, PhD, Vice President, Microbiology discussed the Characterization of Acinetobacter baumannii-calcoaceticus complex (ABC) pathogens isolated at baseline from patients enrolled in the ATTACK Phase 3 trial.
  • In contrast, only 4.6% of isolates had sulbactam-durlobactam (SUL-DUR) MICs >4 mg/L (above the preliminary breakpoint).
  • The ATTACK trial was conducted to evaluate the efficacy and safety of SUL-DUR versus colistin, both in combination with imipenem/cilastatin, for patients with ABC infections, including carbapenem-resistant and multidrug-resistant strains.
  • Notably, only 45% of these isolates were susceptible to imipenem alone while 73% were imipenem-susceptible in the presence of SUL-DUR.

ContraFect Announces Multiple Presentations of New Data Demonstrating the Potential of Its Direct Lytic Agents (DLAs) to Address Antimicrobial Resistance at the 32nd Annual ECCMID Meeting

Retrieved on: 
Monday, April 18, 2022
Family, Acinetobacter baumannii, Osteomyelitis, Levofloxacin, Clinical trial, SOC, MRSA, U.S. Securities and Exchange Commission, Breakthrough therapy, Security (finance), Peptide, Pseudomonas aeruginosa, Meropenem, Tobramycin, Bacteria, Infection, Enterobacter, Campaign, Subclinical infection, Method, Trial of the century, Death, Lysin, Endocarditis, Maintenance, DLA, Forward-looking statement, Area studies, MIC, Biofilm, FDA, Pneumonia, Cystic fibrosis, Vaccine

An estimated 700,000 deaths worldwide each year are attributed to antimicrobial-resistant infections.

Key Points: 
  • An estimated 700,000 deaths worldwide each year are attributed to antimicrobial-resistant infections.
  • We intend to address life threatening infections using our therapeutic product candidates from our platform of DLAs, which include lysins and amurin peptides.
  • Amurin peptides are a novel class of DLAs which exhibit broad-spectrum activity against a wide range of antibiotic-resistant Gram-negative pathogens, including P. aeruginosa, Acinetobacter baumannii, and Enterobacter species.
  • Important factors that could cause actual results to differ include, among others, our ability to develop treatments for drug-resistant infectious diseases.

Melinta Therapeutics Acquires U.S. Rights to TOPROL-XL® (metoprolol succinate) from New American Therapeutics

Retrieved on: 
Wednesday, April 6, 2022
Health, Infectious Diseases, Clinical Trials, Pharmaceutical, Cardiology, Biotechnology, Risk, Hypoglycemia, Therapy, Meropenem, First-degree atrioventricular block, Clonidine, Blood pressure, Cardiac arrest, NYHA, III, Allergy, Moyamoya disease, Diabetes, Angina, Diltiazem, Hyperthyroidism, Vaborbactam, Cardiogenic shock, AstraZeneca, Heart, Patient, Hypertension, Bradycardia, Peripheral artery disease, CEO, Adrenaline, Sinus node dysfunction, Pheochromocytoma, LLC, Heart block, Acquisition, Stroke, Verapamil, Injection, Castleman disease, Heart failure, Purkinje fibers, Digitalis, FDA, Minocycline, Infarction, Hypersensitivity, Pharmaceutical industry, Medical device, Melinta Therapeutics

We will continue to aggressively pursue portfolio expansion that aligns with our mission of providing innovative therapies for acute and life-threatening illnesses.

Key Points: 
  • We will continue to aggressively pursue portfolio expansion that aligns with our mission of providing innovative therapies for acute and life-threatening illnesses.
  • We are extremely proud of our work to provide access to this lifesaving medication, said Michael Anderson, CEO, New American Therapeutics.
  • Melinta Therapeutics, LLC provides innovative therapies to people impacted by acute and life-threatening illnesses.
  • At Melinta, were visionaries dedicated to innovation while staying grounded in what matters most: patients.

Biocomposites to present data on STIMULAN® at American Academy of Orthopaedic Surgeons Annual Meeting

Retrieved on: 
Tuesday, March 15, 2022
Podiatry, Doctor of Philosophy, Time, Immunity, Pseudomonas aeruginosa, Meropenem, Global health, Staphylococcus aureus, OLC, Annual general meeting, Ohio State University, Vancomycin, CME, American Academy, Infection, Spine, AAOS, Foot, Research, Academy, Ankle, Biofilm, Trauma, Tobramycin, Genetically modified bacteria, Rifampicin, Surgeon, Pharmaceutical industry, Orthopedic surgery

The study also demonstrated the importance of sufficient coverage of beads in order to eradicate the biofilm.

Key Points: 
  • The study also demonstrated the importance of sufficient coverage of beads in order to eradicate the biofilm.
  • Michael Harris, Chief Executive Officer of Biocomposites, added: "Biocomposites is excited to present new STIMULAN data at this distinguished annual meeting as part of our ongoing commitment to share insights and deliver innovative products that help surgeons with their infection management."
  • Biocomposites products are now used in over 120,000 procedures per annum and sold in more than 40 countries around the world.
  • Founded in 1933, the Academy is the preeminent provider of musculoskeletal education to orthopaedic surgeons and others in the world.

Biocomposites to present data on STIMULAN® at American Academy of Orthopaedic Surgeons Annual Meeting

Retrieved on: 
Tuesday, March 15, 2022
Podiatry, Doctor of Philosophy, Time, Immunity, Pseudomonas aeruginosa, Meropenem, Global health, Staphylococcus aureus, OLC, Annual general meeting, Ohio State University, Vancomycin, CME, American Academy, Infection, Spine, AAOS, Foot, Research, Academy, Ankle, Biofilm, Trauma, Tobramycin, Genetically modified bacteria, Rifampicin, Surgeon, Pharmaceutical industry, Antibiotics, Orthopedic surgery, EU

KEELE, England, March 15, 2022 /PRNewswire/ -- Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for use in infection management in bone and soft tissue, is pleased to announce that Professor Paul Stoodley will be presenting the results of his in vitro study into the effectiveness of different dual combination antibiotics in killing antibiotic resistant and tolerant persister cells in lawn biofilms of Staphylococcus aureus and Pseudomonas aeruginosa at the American Academy of Orthopaedic Surgeons Annual Meeting (AAOS), being held in Chicago, 22-26 March 2022.

Key Points: 
  • The study also demonstrated the importance of sufficient coverage of beads in order to eradicate the biofilm.
  • Michael Harris, Chief Executive Officer of Biocomposites, added: "Biocomposites is excited to present new STIMULAN data at this distinguished annual meeting as part of our ongoing commitment to share insights and deliver innovative products that help surgeons with their infection management."
  • Biocomposites products are now used in over 120,000 procedures per annum and sold in more than 40 countries around the world.
  • Founded in 1933, the Academy is the preeminent provider of musculoskeletal education to orthopaedic surgeons and others in the world.